viltepso Drug Patent Profile
✉ Email this page to a colleague
When do Viltepso patents expire, and what generic alternatives are available?
Viltepso is a drug marketed by Nippon Shinyaku and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-three patent family members in twenty countries.
The generic ingredient in VILTEPSO is viltolarsen. One supplier is listed for this compound. Additional details are available on the viltolarsen profile page.
DrugPatentWatch® Generic Entry Outlook for Viltepso
Viltepso was eligible for patent challenges on August 12, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 31, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for viltepso?
- What are the global sales for viltepso?
- What is Average Wholesale Price for viltepso?
Summary for viltepso
| International Patents: | 53 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Drug Prices: | Drug price information for viltepso |
| What excipients (inactive ingredients) are in viltepso? | viltepso excipients list |
| DailyMed Link: | viltepso at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for viltepso
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for viltepso
viltepso is protected by two US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of viltepso is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting viltepso
Antisense nucleic acids
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
Antisense nucleic acids
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting viltepso
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for viltepso
When does loss-of-exclusivity occur for viltepso?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 11296882
Patent: Antisense nucleic acid
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 09637
Patent: ACIDE NUCLEIQUE ANTISENS (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
China
Patent: 3154245
Patent: Antisense nucleic acid
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0160336
Estimated Expiration: ⤷ Sign Up
Patent: 0191770
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 17367
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 12917
Estimated Expiration: ⤷ Sign Up
Patent: 18211
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 12917
Patent: ACIDE NUCLÉIQUE ANTISENS (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 18211
Patent: ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Sign Up
Patent: 43341
Patent: ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Sign Up
Patent: 81655
Patent: ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 27321
Estimated Expiration: ⤷ Sign Up
Patent: 46364
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 2012029986
Patent: アンチセンス核酸
Estimated Expiration: ⤷ Sign Up
Patent: 63655
Estimated Expiration: ⤷ Sign Up
Patent: 41728
Estimated Expiration: ⤷ Sign Up
Patent: 93343
Estimated Expiration: ⤷ Sign Up
Patent: 65932
Estimated Expiration: ⤷ Sign Up
Patent: 47430
Estimated Expiration: ⤷ Sign Up
Patent: 67619
Estimated Expiration: ⤷ Sign Up
Patent: 67620
Estimated Expiration: ⤷ Sign Up
Patent: 67621
Estimated Expiration: ⤷ Sign Up
Patent: 67636
Estimated Expiration: ⤷ Sign Up
Patent: 14054250
Patent: ANTISENSE NUCLEIC ACIDS
Estimated Expiration: ⤷ Sign Up
Patent: 16104021
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 18027083
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 19062913
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 20072724
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 21072820
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 21072821
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 21072822
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 21104037
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 23036865
Patent: アンチセンス核酸
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 18211
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 12917
Estimated Expiration: ⤷ Sign Up
Patent: 18211
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 18211
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 67664
Patent: АНТИСМЫСЛОВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Sign Up
Patent: 13114396
Patent: АНТИСМЫСЛОВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01600111
Patent: ACIDI NUCLEICI ANTISENSO
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 649
Patent: ANTISENS NUKLEINSKE KISELINE (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Sign Up
Patent: 361
Patent: ANTISENS NUKLEINSKE KISELINE (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 12917
Estimated Expiration: ⤷ Sign Up
Patent: 18211
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1310569
Estimated Expiration: ⤷ Sign Up
Patent: 130069762
Patent: ANTISENSE NUCLEIC ACID
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 67411
Estimated Expiration: ⤷ Sign Up
Patent: 50748
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 41024
Estimated Expiration: ⤷ Sign Up
Patent: 1215408
Patent: Antisense nucleic acid
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering viltepso around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
